Sana Biotechnology (NASDAQ:SANA) Upgraded to Outperform at Citizens Jmp

Citizens Jmp upgraded shares of Sana Biotechnology (NASDAQ:SANA) from a market perform rating to an outperform rating in a report published on Tuesday, MarketBeat reports. The firm currently has $5.00 price target on the stock.

Several other research analysts have also weighed in on SANA. HC Wainwright lifted their price objective on Sana Biotechnology from $8.00 to $11.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. TD Cowen upgraded Sana Biotechnology from a “hold” rating to a “buy” rating in a research note on Wednesday, January 8th. Finally, Jefferies Financial Group began coverage on Sana Biotechnology in a research note on Friday, March 14th. They issued a “buy” rating and a $7.00 target price for the company. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $10.80.

Sana Biotechnology Stock Down 17.7 %

Shares of NASDAQ:SANA opened at $2.28 on Tuesday. The business has a fifty day simple moving average of $3.06 and a 200 day simple moving average of $3.20. Sana Biotechnology has a 12-month low of $1.52 and a 12-month high of $10.50. The firm has a market cap of $509.05 million, a P/E ratio of -1.63 and a beta of 1.63.

Sana Biotechnology (NASDAQ:SANA) last posted its quarterly earnings data on Monday, March 17th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.02. As a group, equities research analysts expect that Sana Biotechnology will post -1.16 EPS for the current year.

Insider Buying and Selling at Sana Biotechnology

In other Sana Biotechnology news, insider Fmr Llc sold 290,912 shares of Sana Biotechnology stock in a transaction dated Wednesday, January 8th. The stock was sold at an average price of $6.49, for a total transaction of $1,888,018.88. Following the completion of the transaction, the insider now owns 4,541,511 shares in the company, valued at approximately $29,474,406.39. The trade was a 6.02 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 31.10% of the company’s stock.

Hedge Funds Weigh In On Sana Biotechnology

Several hedge funds have recently modified their holdings of the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Sana Biotechnology by 10.0% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 279,282 shares of the company’s stock worth $455,000 after buying an additional 25,383 shares in the last quarter. Vident Advisory LLC lifted its position in shares of Sana Biotechnology by 42.3% during the 4th quarter. Vident Advisory LLC now owns 43,291 shares of the company’s stock worth $71,000 after buying an additional 12,861 shares in the last quarter. Squarepoint Ops LLC lifted its position in shares of Sana Biotechnology by 45.3% during the 4th quarter. Squarepoint Ops LLC now owns 178,431 shares of the company’s stock worth $291,000 after buying an additional 55,625 shares in the last quarter. Two Sigma Advisers LP lifted its position in shares of Sana Biotechnology by 677.0% during the 4th quarter. Two Sigma Advisers LP now owns 209,000 shares of the company’s stock worth $341,000 after buying an additional 182,100 shares in the last quarter. Finally, Two Sigma Investments LP lifted its position in shares of Sana Biotechnology by 228.4% during the 4th quarter. Two Sigma Investments LP now owns 480,298 shares of the company’s stock worth $783,000 after buying an additional 334,042 shares in the last quarter. Institutional investors own 88.23% of the company’s stock.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.